Financial Feasibility of BPaL(M) Under Pretomanid Price Scenarios - China, 2023-2024. [PDF]
China CDC WklyRen J +10 more
europepmc +1 more source
Assessing Eligibility for Anticancer Drug Health Insurance Reimbursement Using Large Language Models: Benchmark Development and Comparative Study. [PDF]
J Med Internet ResSeo J, Kim T, Kim JH.
europepmc +1 more source
The Reality of Benign Prostatic Hyperplasia Surgery Price and Reimbursement Across Top United States Hospitals. [PDF]
Urol PractMurray G +4 more
europepmc +1 more source
Claims Reimbursement Analysis of the National Health Insurance Scheme in Ghana [PDF]
Value in Health, 2014 openaire +2 more sources
Real-World Evidence for Drug Value Assessment in China: Learning from International Experiences. [PDF]
Drugs Real World OutcomesHartzema AG, Gehchan A, Guo JD, Xuan J.
europepmc +1 more source
Clinic-based Treatment of Type B Ulnar Polydactyly Saves Costs Compared With Treatment in the Operating Room. [PDF]
Plast Reconstr Surg Glob OpenSingh NP +5 more
europepmc +1 more source
Time Frame Analysis of Medical Device Approval, New Health Technology Assessment, and Reimbursement Decision-Making in Korea. [PDF]
J Korean Med SciKim JH.
europepmc +1 more source
Residents' preferences for inclusive commercial supplementary medical insurance: a discrete choice experiment. [PDF]
Health Econ RevFeng Y, Li G, Wu S, Sun Q, Xi X, Wang E.
europepmc +1 more source
Access to orphan drugs in adults with inherited metabolic diseases in Switzerland: a single-center retrospective cohort study. [PDF]
Orphanet J Rare DisAntoni G +4 more
europepmc +1 more source
Economic evidence on provider-level implications of direct posterior amalgam alternatives following the EU phase-out: a scoping review. [PDF]
BMJ OpenOesterreicher J, Herz MM.
europepmc +1 more source